Low O6‐methylguanine‐DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours
- 6 July 2009
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 71 (2) , 226-233
Abstract
Summary: Context Recent case reports detail the successful use of temozolomide in the management of aggressive pituitary tumours. O6‐methylguanine‐DNA methyltransferase (MGMT) is a DNA repair protein that counteracts the effect of temozolomide.Objective To study MGMT expression in pituitary tumours and consider whether MGMT expression is associated with response to temozolomide therapy in aggressive pituitary tumours.Patients We report two patients with aggressive pituitary tumours treated with temozolomide, one who responded to temozolomide and the other who did not. MGMT expression was assessed in a further 88 archived pituitary tumour samples.Design MGMT expression was assessed by immunohistochemistry. MGMT promoter methylation was studied by methylation‐specific polymerase chain reaction (MSP), sequencing of MGMT was performed and loss of heterozygosity (LOH) analysis undertaken.Results Low MGMT expression and MGMT promoter methylation were found in the pituitary tumour of the patient who responded to temozolomide. Conversely, high MGMT expression was seen in the patient demonstrating a poor response to temozolomide. Eleven out of 88 archived tumour samples (13%) had low MGMT expression. Prolactinomas were more likely to have low MGMT expression compared with other pituitary tumour subtypes (P < 0·001). There was no significant difference in MGMT expression between invasive and noninvasive tumours, or between recurrent and nonrecurrent tumours. A significant inverse correlation was found between MGMT expression and promoter methylation (P = 0·012).Conclusion MGMT expression as assessed by immunohistochemistry may predict response to temozolomide therapy in patients with aggressive pituitary tumours. MGMT promoter methylation is likely to explain low MGMT expression in some, but not all, pituitary tumours.Keywords
This publication has 40 references indexed in Scilit:
- Molecular genetic markers as predictors of response to chemotherapy in gliomasCurrent Opinion in Oncology, 2007
- Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytomaWorld Journal of Surgical Oncology, 2007
- Genetic association and functional studies of major polymorphic variants of MGMTDNA Repair, 2007
- Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide TreatmentClinical Cancer Research, 2007
- Long-term response of pituitary carcinoma to temozolomideJournal of Neurosurgery, 2006
- Antitumour effects of temozolomide in a man with a large, invasive prolactin‐producing pituitary neoplasmClinical Endocrinology, 2006
- Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying MechanismsClinical Cancer Research, 2006
- O 6 -methylguanine methyltransferase in colorectal cancers: detection of mutations, loss of expression, and weak association with G:C>A:T transitionsGut, 2005
- Tumor Progression Through Epigenetic Gene Silencing of O6−Methylguanine-DNA Methyltransferase in Human Biliary Tract CancersAnnals of Surgical Oncology, 2005
- Somatic mutations in the RET proto‐oncogene in sporadic medullary thyroid carcinomaClinical Endocrinology, 1996